Jacobs Levy Equity Management
EGRX

Jacobs Levy Equity Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121,559
Closed -$453K – 1068
2024
Q3 		$453K Buy
+121,559
New +$580K ﹤0.01% 842
2024
Q2 		– Sell
-10,215
Closed -$53.5K – 1073
2024
Q1 		$53.5K Sell
10,215
-5,353
-34% -$29.4K ﹤0.01% 924
2023
Q4 		$81.4K Buy
15,568
+3,982
+34% +$39.3K ﹤0.01% 960
2023
Q3 		$183K Buy
+11,586
New +$208K ﹤0.01% 927
2023
Q1 		– Sell
-10,531
Closed -$308K – 1078
2022
Q4 		$308K Sell
10,531
-21,846
-67% -$695K ﹤0.01% 861
2022
Q3 		$855K Buy
32,377
+4,584
+16% +$168K 0.01% 739
2022
Q2 		$1.24M Sell
27,793
-69,097
-71% -$3.17M 0.01% 709
2022
Q1 		$4.79M Sell
96,890
-45,802
-32% -$2.2M 0.03% 438
2021
Q4 		$7.27M Sell
142,692
-20,407
-13% -$1.06M 0.05% 360
2021
Q3 		$9.1M Sell
163,099
-8,741
-5% -$430K 0.06% 318
2021
Q2 		$7.36M Buy
171,840
+13,835
+9% +$571K 0.05% 360
2021
Q1 		$6.59M Buy
158,005
+2,935
+2% +$136K 0.05% 376
2020
Q4 		$7.22M Buy
155,070
+20,994
+16% +$982K 0.06% 326
2020
Q3 		$5.7M Buy
134,076
+40,446
+43% +$1.77M 0.06% 310
2020
Q2 		$4.49M Buy
93,630
+30,389
+48% +$1.52M 0.05% 363
2020
Q1 		$2.91M Buy
63,241
+42,381
+203% +$2.13M 0.04% 408
2019
Q4 		$1.25M Buy
20,860
+4,024
+24% +$240K 0.01% 643
2019
Q3 		$952K Buy
16,836
+590
+4% +$33.2K 0.01% 620
2019
Q2 		$905K Buy
+16,246
New +$847K 0.01% 658

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Jacobs Levy Equity Management's EGRX Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 121,559 shares — an estimated $453K sold.

Jacobs Levy Equity Management first reported a position in EGRX in Q2 2019 and held it in 19 quarters. The position peaked at $9.1M in Q3 2021. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 121,559 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $453K.
  • Jacobs Levy Equity Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 19 quarters.
  • Jacobs Levy Equity Management's Eagle Pharmaceuticals, Inc. position peaked at $9.1M in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.